The Role of Specialty Pharmacy and the Opportunity to Manage Moderate-to-Severe Atopic Dermatitis Web Activity


Paul Yamauchi, MD, PhD
Clinical Assistant Professor of Dermatology
David Geffen School of Medicine at UCLA
Adjunct Associate Professor
John Wayne Cancer Institute
Dermatology Institute & Skin Care Center
Clinical Science Institute

Click here for biography

Cheryl Allen, RPh, BS Pharm, MBA
Vice President, Industry Relations

Click here for biography



Atopic dermatitis (AD), or eczema, is a complex, chronic, relapsing inflammatory skin disease marked by pruritus and skin irritation. Current prevalence is estimated to be 15%–30% among children and 2%–10% among adults, although its prevalence in adults may be underestimated. Dysregulation of both the innate and adaptive immune systems are believed to be involved in the pathogenesis of AD and the condition is frequently accompanied by other allergic disorders including food allergy, allergic rhinitis, and asthma. Recent studies have documented the adverse effects of AD on mental health and quality of life and new evidence suggests a relationship between AD and other chronic, nonallergic conditions including obesity, cardiovascular disease, autoimmunity, and malignancies. This activity is focused on AD diagnosis and treatment, impact of emerging therapies, adherence to therapy, and practical approaches for specialty pharmacists to implement and improve outcomes for patients with AD.

After completing this activity, the participant should be better able to:


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-18-164-H01-P

Type of Activity: Application

For Pharmacists: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to the CPE Monitor as required. After receipt of a completed activity evaluation form, you will be provided with instructions to have your credit immediately uploaded to the CPE Monitor.   

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Name of Faculty or Presenter Reported Financial Relationship
Paul Yamauchi, MD, PhD

Consulting fees (ex. advisory boards) – Novartis Pharmaceuticals Corporation, Lilly USA, LLC, Amgen, Inc., AbbVie, Inc., Janssen, Valeant Pharmaceuticals

Fees for non-CME/CE Services Received Directly from a Commercial Interest or their agents (ex. speakers’ bureaus) – Novartis Pharmaceuticals Corporation, Lilly USA, LLC, Amgen, Inc., AbbVie, Inc., Janssen Pharmaceuticals
Cheryl Allen, RPh, BS Pharm, MBA  No financial interest/relationships relating to the topic of this activity

The PIM planners and managers have nothing to disclose.  The Impact Education, LLC planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation and Request for Credit
There are no fees for participating and receiving CPE credit for this activity. During the period of July 19, 2018, through January 31, 2020, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full activity, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.


There is no fee for this educational activity.